143 related articles for article (PubMed ID: 12523881)
1. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
[TBL] [Abstract][Full Text] [Related]
2. Morphometric effects of long-term exposure to latanoprost.
Cracknell KP; Grierson I; Hogg P
Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
[TBL] [Abstract][Full Text] [Related]
3. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
Yildirim N; Sahin A; Kara S; Baycu C
Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
[TBL] [Abstract][Full Text] [Related]
5. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.
Pfeiffer N; Grierson I; Goldsmith H; Hochgesand D; Winkgen-Böhres A; Appleton P
Arch Ophthalmol; 2001 Feb; 119(2):191-6. PubMed ID: 11176979
[TBL] [Abstract][Full Text] [Related]
6. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
[TBL] [Abstract][Full Text] [Related]
8. Analysis of irises with a latanoprost-induced change in iris color.
Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
[TBL] [Abstract][Full Text] [Related]
9. Histology and fine structure of the iris and outflow system following latanoprost therapy.
Grierson I; Pfeiffer N; Cracknell KP; Appleton P
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
[TBL] [Abstract][Full Text] [Related]
10. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
[TBL] [Abstract][Full Text] [Related]
11. Iris morphology.
Teus MA; Arranz-Marquez E
Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
[No Abstract] [Full Text] [Related]
12. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
13. Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study.
Cracknell KP; Grierson I; Hogg P; Majekodunmi AA; Watson P; Marmion V
Exp Eye Res; 2006 Jun; 82(6):986-93. PubMed ID: 16297910
[TBL] [Abstract][Full Text] [Related]
14. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
Berthold S; Pfeiffer N
Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
[TBL] [Abstract][Full Text] [Related]
15. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
16. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
Latanoprost-Induced Iris Pigmentation Study Group
Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
[TBL] [Abstract][Full Text] [Related]
17. Incidence of iris colour change in latanoprost treated eyes.
Teus MA; Arranz-Márquez E; Lucea-Suescun P
Br J Ophthalmol; 2002 Oct; 86(10):1085-8. PubMed ID: 12234883
[TBL] [Abstract][Full Text] [Related]
18. The effect of latanoprost on aqueous humor PGF2alpha levels in glaucoma patients.
Güven D; Karakurt A; Saban E; Hasiripi H
Int Ophthalmol; 1999; 23(2):91-6. PubMed ID: 11196126
[TBL] [Abstract][Full Text] [Related]
19. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
20. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
